1. The current situation:

Dementia, also known as Alzheimer's disease (AD), is a neurodegenerative disorder characterized by a cognitive decline with memory loss.
As a matter of fact, the disease begins 10 to 15 years before the onset of the first clinical symptoms. Therefore, in recent years there has been much interest in the early stages of AD, attempting to identify the pathogenic mechanisms of AD and to define early treatment modalities.

This project starts with its unique process right here.
Even in the early phase, the pathological processes are compensated over a longer period by compensatory mechanisms in the central nervous system. The disease remains unnoticed externally for a very long time, but can be determined by special biomarkers in the blood.

The statistic of dementia patients is increasing.
In 2015, there were 9.9 million new dementia patients.
This means: 46.8 million people with dementia - this number is doubling every 20 Years. By 2050, there will be an estimated 131.5 million people with dementia worldwide. The costs for the health sector are enormous. As early as 2018, the costs of dementia were around 1 Billion euros.

Also, the families carry a larg financial burden. It is difficult to quantify the care-related consequences of the relatives and the care expenses in the family, as there are many indirect costs involved. However, delaying home admission and supporting family care at the same time are considered extremely cost-relevant.



Quelle: Schweizerische Alzheimervereinigung, Yverdon-les-Bains, 2012.

For years our partner has been working on the early detection of AD and has developed a safe and secure, cost-saving method to determine the disease at an early stage by identifying certain biomarkers in the blood.

ENTREPRENEURIAL • INDEPENDENT • PERSONAL

NRG AG
Project Management

Aubündt 36
LI-9490 Vaduz

www.nrg-ag.li
mail@nrg-ag.li

Phone: +423 231 2322
Fax: +423 236 51 91

Representation of the
NRG Aktiengesellschaft
in Berlin
Represented by:
Olaf Lange
Kurfürstendamm 130, 10711 Berlin
Phone: +49 30 2084 98937

2. The market and the goals of the company:



There are about 10% of diagnoses in a MEMORY CLINIC and 90% by the family doctors.
However, as primary care physicians make the diagnosis mainly through simple neuropsychology such as dichotomous yes / no assessments, 50% remain without diagnosis. 20% to 30% of patients even leave the practice with misdiagnosis such as depression, memory deficiencies due to side effects of medication, metabolic disorders, drug abuse, vitamin or mineral deficiency.

Our partner pursues the following goals with the rapid dissemination of the procedure:

- The ability to recognize the Alzheimer's diagnosis years earlier, thereby saving costs and improving the therapeutic options of patients.
- To identify the 25% of patients diagnosed with depression earlier than Alzheimer's patients and provide better medical care
- 35% of all dementia cases are potentially more treatable through this screening.
- To reduce the frequent causes of hospitalizations such as fractures, diabetes and lung diseases and others, as the dementia disease can be detected earlier.
- Reducing costs in the health sector and for families and relatives

3. The unique selling point:

The method is based, as few previous methods, on the examination of the blood via the Immunoassay method. Unique, however, is the detection of certain biomarkers that occur in the development of Alzheimer's disease in altered concentrations.
Using a specific algorithm, the individual values are combined into a reliable result and lead to a 99% certain diagnosis with further medical examinations.

Advantages:

- The method is with costs of 200 EUR per test just 7% cheaper than the test costs of a clinical diagnosis (about 2,900 EUR).
- The test is patient-friendly and can be summarized with simple standard laboratory equipment.
- The feasibility studies are completed; all reagents and components were validated.
- The partners are ISO13485 verified; contracts for the completion of the product are signed
- The software was developed according to IEC62304 and is very advanced
- The test can be performed as a routine check-up with the family doctor.
- The test accuracy is 96%
- Is significantly cheaper than previous Alzheimer test procedures
- The test will introduce a meaningful and timely individualized therapeutic intervention.
- In December 2018, an EU patent was granted for the proceedings; Patents in nine others countries were submitted.

NRG AG
Project Management

Aubündt 36
LI-9490 Vaduz

www.nrg-ag.li
mail@nrg-ag.li

Phone: +423 231 2322
Fax: +423 236 51 91

Representation of the
NRG Aktiengesellschaft
in Berlin
Represented by:
Olaf Lange
Kurfürstendamm 130, 10711 Berlin
Phone: +49 30 2084 98937

4. What is the vision of the company?

Worldwide, clinics and distribution partners are available. A global gap-filling coverage by multimedia marketing strategies and social media is aimed at. Most of the marketing will be supported by KOLs (opinion leaders in the healthcare industry), research and development collaborations, validation studies and thematically relevant conferences. These networks already exist. It is still looked for strategic partners for further marketing.

The goal until 2020 is for doctors to be able to conduct this blood test using laboratories to provide a cost-effective early diagnosis of Alzheimer's disease.

5. Which financing is needed?

Financing partners are searched for 1-2 years.
The valuation of the company is over 7 million EUR pre-money.

The distribution of costs for the current year is roughly as follows:

Salaries, infrastructure, insurance	1.100.000,00 €
Assay Development, R&D	1.200.000,00 €
Production first batch	300.000,00 €
Validation studies	300.000,00 €
Marketing & travel expenses	270.000,00 €
Clinical software	90.000,00 €
Regulations (CE/ISO13485)	90.000,00 €
Legal / finance / consulting	200.000,00 €
Patent	50.000,00 €
Total	3.600.000,00 €

In order to ensure the marketing and further development of the method in 2019 approximately EUR 3.6 million are needed. In total, the capital requirement amounts to just under EUR 9 million. To break-even is the goal in the year 2021.

ENTREPRENEURIAL • INDEPENDENT • PERSONAL

NRG AG
Project Management

Aubündt 36
LI-9490 Vaduz

www.nrg-ag.li
mail@nrg-ag.li

Phone: +423 231 2322
Fax: +423 236 51 91

Representation of the
NRG Aktiengesellschaft
in Berlin
Represented by:
Olaf Lange
Kurfürstendamm 130, 10711 Berlin
Phone: +49 30 2084 98937